Production method of thiazole derivative

ABSTRACT

Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A 2A  receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson&#39;s disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: 
                         
(wherein R 1  represents furyl, R 4 , R 5  and R 6  are the same or different and each represents lower alkyl or aryl, R 2  represents pyridyl or tetrahydropyranyl, and X 1  represents halogen).

TECHNICAL FIELD

The present invention relates to a production method of a thiazolederivative useful as an adenosine A_(2A) receptor antagonist, a crystalof the thiazole derivative or a monohydrate thereof, and the like.

BACKGROUND ART

It is known that a thiazole derivative represented by the followingformula (I) or a pharmaceutically acceptable salt thereof has anadenosine A_(2A) receptor antagonistic action, and is useful as atherapeutic drug for, for example, Parkinson's disease (see patentdocuments 1 and 2). In addition, a thiazole derivative useful as atherapeutic agent for sleep disorder, analgesic resistance to opioid,migraine, movement disorder, depression, anxiety disorder and the likeis known (see patent documents 3, 4, 5, 6, 7 and 8). As these thiazolederivatives, compounds represented by the following formulas (IA), (IB),(IC), (ID) and the like, and the like are specifically known (see patentdocuments 1, 3, 4, 5, 6, 7 and 8).

(wherein R¹ represents furyl, R² represents pyridyl ortetrahydropyranyl, R³ represents aryl, aralkyl, an aromatic heterocyclicgroup, aromatic heterocyclylalkyl, aliphatic heterocyclylalkyl ortetrahydropyranyloxy, or these groups substituted by 1 to 3 substituentsselected from the group consisting of halogen; lower alkyl optionallysubstituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl;and vinyl)

As production methods of these thiazole derivatives, the following threeproduction methods (Schemes 1-3) are known (see patent document 1).

(wherein R¹⁰ represents furyl or the like, Hal represents halogen, Phrepresents phenyl, R¹² represents as defined above for R² or the like,and R¹¹ represents as defined above for R³ or the like)

(wherein R¹⁰, R¹¹ and R¹² are each as defined above)

Other than the above, for example, a method including reactingα-halomethyl ketone and an N-(aminomethylene)thiourea derivative (seenon-patent documents 1-4), a method including reacting α-halomethylketone and an N-acyl-thiourea derivative (see non-patent documents 3-6)and the like are also known.

More specifically, the compounds represented by the above-mentionedformulas (IA), (IB), (IC) and (ID) are described in patent document 1 asExamples 504, 508, 557 and 253.

DOCUMENT LIST Patent Documents

-   patent document 1: WO 2005/063743-   patent document 2: WO 2006/137527-   patent document 3: WO 2007/015528-   patent document 4: WO 2009/145289-   patent document 5: WO 2010/010908-   patent document 6: WO 2010/126082-   patent document 7: WO 2011/027805-   patent document 8: WO 2011/027806

Non-Patent Documents

non-patent document 1: Indian Journal of Chemistry, 1970, vol. 8, p.1145

-   non-patent document 2: Indian Journal of Chemistry, 1978, vol.    16B, p. 749-   non-patent document 3: Journal of Chemical Society, Perkin    Transactions I, 1979, p. 1762-   non-patent document 4: Journal of Chemical Society, Perkin    Transactions I, 1987, p. 1153-   non-patent document 5: Zeitschrift für Chemie, 1974, vol. 14, p. 470-   non-patent document 6: Indian Journal of Chemistry, 1986, vol.    25B, p. 446

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

An object of the present invention is to provide an industrialproduction method of a compound represented by the formula (I), whichhas an adenosine A_(2A) receptor antagonistic action and is useful as atherapeutic agent for, for example, Parkinson's disease, sleep disorder,analgesic resistance to opioid, migraine, movement disorder, depression,anxiety disorder and the like, and the like. Also, the object includesprovision of a crystal of a compound represented by the formula (IA) ora monohydrate thereof, and a production method thereof, and the like.

Means of Solving the Problems

The present invention relates to the following (1)-(31).

(1) A production method of a compound represented by the formula (C),comprising (i) a step of reacting a compound represented by the formula(A) and a compound represented by the formula (B):

(wherein R¹ represents furyl, R⁴, R⁵ and R⁶ are the same or differentand each represents lower alkyl or aryl, R² represents pyridyl ortetrahydropyranyl, and X¹ represents halogen).(2) The production method according to (1), wherein X¹ is a chlorineatom, a bromine atom or an iodine atom.(3) The production method according to (1), wherein X¹ is a bromineatom.(4) The production method according to any of (1)-(3), wherein R⁴, R⁵and R⁶ are each methyl.(5) The production method according to any of (1)-(4), wherein R¹ is2-furyl.(6) A production method of a compound represented by the formula (I)comprising the step described in any of (1)-(5):

(wherein R¹ and R² are each as defined above, R³ represents aryl,aralkyl, an aromatic heterocyclic group, aromatic heterocyclylalkyl,aliphatic heterocyclylalkyl or tetrahydropyranyloxy, or these groupssubstituted by 1 to 3 substituents selected from the group consisting ofhalogen; lower alkyl optionally substituted by lower alkoxy ormorpholino; lower alkoxy; lower alkanoyl; and vinyl).(7) The production method according to (6), further comprising (ii) astep of obtaining a compound represented by the formula (D) by treatinga compound represented by the formula (C) with an acid:

(wherein R¹, R², R⁴, R⁵ and R⁶ are each as defined above), and (iii) astep of obtaining a compound represented by the formula (I) by reactinga compound represented by the formula (D) and a compound represented bythe formula (E):

(wherein Y represents halogen or hydroxy, and R², R² and R³ are each asdefined above).(8) The production method according to (7), wherein the acid in step(ii) is hydrochloric acid or trifluoroacetic acid.(9) The production method according to (7) or (8), wherein Y is hydroxy.(10) The production method according to (9), wherein the reaction instep (iii) is performed in the presence of 1,3-dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(EDC), 1,1′-carbonyldiimidazole (CDI) or propylphosphonic anhydride(T3P).(11) The production method according to (9), wherein the reaction instep (iii) is performed in the presence of CDI.(12) The production method according to any of (1)-(11), wherein R² is4-tetrahydropyranyl.(13) The production method according to any of (6)-(12), wherein R³ is2-methylpyridin-5-yl, 2-methylpyrimidin-5-yl,5,6-dihydro-2H-pyridylmethyl or 4-tetrahydropyranyloxy.(14) The production method according to any of (6)-(12), wherein R³ is2-methylpyridin-5-yl.(15) The production method according to any of (6)-(11), wherein R¹ is2-furyl, R² is 4-tetrahydropyranyl, and R³ is 2-methylpyridin-5-yl.(16) A production method of a compound represented by the formula (A),comprising a step of reacting a compound represented by the formula (P),a compound represented by the formula (Q) and a thiocyanate salt:

(wherein X² represents halogen, and R¹, R⁴, R⁵ and R⁶ are each asdefined above).(17) The production method according to (16), wherein the thiocyanatesalt is sodium thiocyanate or potassium thiocyanate.(18) The production method according to (16) or (17), wherein R¹ is2-furyl, and R⁴, R⁵ and R⁶ are each methyl.(19) The production method according to any of (16)-(18), wherein thereaction is performed in tetrahydrofuran (THF).(20) A crystal of a compound represented by the formula (IA), whereinthe compound is a monohydrate:

(21) The crystal according to (20), which has peaks at 8.1° and 12.0°for the angles of diffraction (2θ±0.2°) as determined by powder X-raydiffraction.(22) The crystal according to (20) or (21), which has peaks at 16.3°,21.8° and 23.0° for the angles of diffraction (2θ±0.2°) as determined bypowder X-ray diffraction.(23) The crystal according to any of (20)-(22), which has peaks at14.7°, 21.1°, 24.4°, 24.7° and 28.3° for the angles of diffraction(2θ±0.2°) as determined by powder X-ray diffraction.(24) A crystal of a compound represented by the formula (IA), whereinthe compound is an anhydride:

(25) The crystal according to (24), which has peaks at 8.3° and 19.1°for the angles of diffraction (2θ±0.2°) as determined by powder X-raydiffraction.(26) The crystal according to (24) or (25), which has peaks at 21.2°,23.8° and 27.0° for the angles of diffraction (2θ±0.2°) as determined bypowder X-ray diffraction.(27) The crystal according to any of (24)-(26), which has peaks at12.6°, 16.5°, 19.5°, 20.8° and 22.4° for the angles of diffraction(2θ±0.2°) as determined by powder X-ray diffraction.(28) A production method of the crystal described in any of (20)-(23),comprising a step of crystallizing a compound represented by the formula(IA) from acetone-water.(29) A production method of the crystal described in any of (24)-(27),comprising a step of crystallizing a compound represented by the formula(IA) from isobutyl alcohol.(30) The production method according to (28) or (29), wherein thecompound represented by the formula (IA) to be used as a startingmaterial is monohydrate.(31) The production method according to any of (28)-(30), wherein thecompound represented by the formula (IA) to be used as a startingmaterial is a compound obtained by the production method described inany of (6)-(15).

Effect of the Invention

According to the present invention, a production method of a compoundrepresented by the formula (I), which has an adenosine A_(2A) receptorantagonistic action and is useful as a therapeutic agent for, forexample, Parkinson's disease, sleep disorder, analgesic resistance toopioid, migraine, movement disorder, depression, anxiety disorder andthe like, a production method of a compound represented by the formula(C), which is useful as an production intermediate for a compoundrepresented by the formula (I), a crystal of a compound represented bythe formula (IA) or a monohydrate thereof and a production methodthereof and the like are provided. The production methods of the presentinvention are useful as industrial production methods of a drugsubstance of a pharmaceutical product. In addition, a crystal of acompound represented by the formula (IA) or a monohydrate thereof of thepresent invention is useful as a drug substance of a pharmaceuticalproduct.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a powder X-ray diffraction pattern of a crystal of compoundIA monohydrate (HA crystal), wherein the vertical axis shows diffractionintensity (Counts/sec), and the horizontal axis shows diffraction angle(2θ, °).

FIG. 2 shows a powder X-ray diffraction pattern of a crystal of compoundIA anhydride (A crystal), wherein the vertical axis shows diffractionintensity (Counts/sec), and the horizontal axis shows diffraction angle(2θ, °).

FIG. 3 shows a powder X-ray diffraction pattern of a crystal of compoundIA 0.5 ethanolate (EA crystal), wherein the vertical axis showsdiffraction intensity (Counts/sec), and the horizontal axis showsdiffraction angle (2θ, °).

DETAILED DESCRIPTION OF THE INVENTION

In the following, a compound represented by the formula (I) is referredto as compound I. The same applies to the compounds of other formulanumbers.

In the definition of each group in the formulas (I), (A), (B), (C), (E),(P) and (Q):

Examples of the lower alkyl, and the lower alkyl moiety of the loweralkoxy and the lower alkanoyl include linear or branched alkyl having1-10 carbon atoms, and more specific examples thereof include methyl,ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl and thelike.

Examples of the aralkyl include aralkyl having 7-16 carbon atoms, andmore specific examples thereof include benzyl, phenethyl, phenylpropyl,phenylbutyl, phenylpentyl, phenylhexyl, phenylheptyl, phenyloctyl,phenylnonyl, phenyldecyl, naphthylmethyl, naphthylethyl, naphthylpropyl,naphthylbutyl, naphthylpentyl, naphthylhexyl, anthrylmethyl,anthrylethyl and the like.

Examples of the aryl include aryl having 6-14 carbon atoms, and morespecific examples thereof include phenyl, naphthyl, azulenyl, anthryland the like.

Examples of the aromatic heterocyclic group include a 5-membered or6-membered monocyclic aromatic heterocyclic group containing at leastone atom selected from a nitrogen atom, an oxygen atom and a sulfuratom, a bicyclic or tricyclic fused aromatic heterocyclic group wherein3- to 8-membered rings are fused, which contains at least one atomselected from a nitrogen atom, an oxygen atom and a sulfur atom, and thelike, and more specific examples thereof include furyl, thienyl,pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl,triazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl,pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl,benzothiophenyl, benzoxazolyl, benzothiazolyl, isoindolyl, indolyl,indazolyl, benzimidazolyl, benzotriazolyl, oxazolopyrimidinyl,thiazolopyrimidinyl, pyrrolopyridinyl, pyrrolopyrimidinyl,imidazopyridinyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl,phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl,furo[2,3-b]pyridyl, 6,7-dihydro-5H-cyclopenta[b]pyridyl,7,8-dihydro-5H-pyrano[4,3-b]pyridyl,7,8-dihydro-5H-thiopyrano[4,3-b]pyridyl and the like.

Examples of the aromatic heterocyclylalkyl include a group wherein anaromatic heterocyclic group is bonded to alkylene. Examples of thearomatic heterocyclic group include the groups recited as examples ofthe above-mentioned aromatic heterocyclic group, examples of thealkylene include alkylene having 1-10 carbon atoms, and more specificexamples thereof include methylene, ethylene, trimethylene, propylene,tetramethylene, pentamethylene, hexamethylene, heptamethylene,octamethylene, nonamethylene, decamethylene and the like. More specificexamples of aromatic heterocyclylalkyl include pyrrolylmethyl,pyrrolylethyl, thiazolylmethyl, pyridylmethyl, pyridylethyl,pyrimidinylmethyl, pyrimidinylethyl, indolylmethyl,benzoimidazolylmethyl and the like.

Examples of the aliphatic heterocyclylalkyl include a group wherein analiphatic heterocyclic group is bonded to alkylene. Examples of thealiphatic heterocyclic group include a 5-membered or 6-memberedmonocyclic aliphatic heterocyclic group containing at least one atomselected from a nitrogen atom, an oxygen atom and a sulfur atom, abicyclic or tricyclic fused aliphatic heterocyclic group wherein 3- to8-membered rings are fused, which contains at least one atom selectedfrom a nitrogen atom, an oxygen atom and a sulfur atom, and the like,and more specific examples thereof include aziridinyl, azetidinyl,pyrrolidinyl, piperidino, piperidinyl, azepanyl,1,2,5,6-tetrahydropyridyl, imidazolidinyl, pyrazolidinyl, piperazinyl,homopiperazinyl, pyrazolinyl, oxiranyl, tetrahydrofuranyl,tetrahydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyridyl,oxazolidinyl, morpholino, morpholinyl, thioxazolidinyl, thiomorpholinyl,2H-oxazolyl, 2H-thioxazolyl, dihydroindolyl, dihydroisoindolyl,dihydrobenzofuranyl, benzoimidazolidinyl, dihydrobenzooxazolyl,dihydrobenzothioxazolyl, benzodioxolinyl, tetrahydroquinolyl,tetrahydroisoquinolyl, dihydro-2H-chromanyl, dihydro-1H-chromanyl,dihydro-2H-thiochromanyl, dihydro-1H-thiochromanyl,tetrahydroquinoxalinyl, tetrahydroquinazolinyl, dihydrobenzodioxanyl andthe like. Examples of the alkylene include alkylene having 1-10 carbonatoms, and more specific examples thereof include methylene, ethylene,trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene,heptamethylene, octamethylene, nonamethylene, decamethylene and thelike. More specific examples of the aliphatic heterocyclylalkyl include5,6-dihydro-2H-pyridylmethyl, 5,6-dihydro-2H-pyridylethyl,tetrahydro-2H-pyranylmethyl, 5,6-dihydro-2H-pyranylmethyl,5,6-dihydro-2H-pyranylethyl, morpholinomethyl, morpholinoethyl,piperazinylmethyl, oxazolidinylmethyl and the like.

Halogen means each atom of fluorine, chlorine, bromine, iodine.

The production method of compound I (Scheme described below) isspecifically explained below.

(wherein M represents a metal atom such as sodium, potassium and thelike, and R¹, R², R³, R⁴, R⁵, R⁶, X¹, X² and Y are each as definedabove)Step 1

Compound A can be obtained by reacting compound P, compound Q and athiocyanate salt in a suitable solvent. These three reagents (compoundP, compound Q and thiocyanate salt) may be reacted simultaneously, orrespective reagents can also be reacted sequentially in an appropriateorder. Preferably, compound A can be obtained by reacting a thiocyanatesalt and compound P in a suitable solvent, and then adding compound Q tothe obtained reaction mixture to allow for reaction, according to themethod described in, for example, J. C. S. Perkin I, 1153 (1987) and thelike.

While the amount of each reagent to be used is not particularly limited,it is, for example, preferably 0.8-1.5 equivalents, more preferably0.9-1.2 equivalents, of compound Q, and preferably 0.8-1.5 equivalents,more preferably 0.9-1.2 equivalents, of thiocyanate salt, both relativeto compound P.

Examples of the thiocyanate salt include sodium thiocyanate, potassiumthiocyanate and the like, preferably sodium thiocyanate.

While the solvent is not particularly limited, for example, aliphatichydrocarbon such as pentane, hexane, heptane, cyclohexane and the like;aromatic hydrocarbon such as toluene, xylene and the like; halogenatedhydrocarbon such as dichloromethane, chloroform, dichloroethane and thelike; polar solvents such as acetonitrile, dimethyl sulfoxide (DMSO),N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA),N-methyl-2-pyrrolidone (NMP), 1,3-dimethyl-2-imidazolidinone (DMI) andthe like; ethers such as dioxane, THF, diethyl ether, cyclopentyl methylether, 1,2-dimethoxyethane (DME), ethylene glycol dimethyl ether and thelike; esters such as methyl acetate, ethyl acetate, isopropyl acetateand the like, and the like. These may be used alone or as a mixturethereof.

Preferred are THF and the like. The amount of the solvent to be used isnot particularly limited and, for example, 1-50 volume/weight (v/w) isused relative to compound P.

The reaction is performed at a temperature of preferably between −10° C.and 150° C., more preferably 0° C. and 100° C., generally for 5 min-72hr.

Compound P and compound Q can be obtained as commercially availableproducts.

Step 2 Compound C can be obtained by reacting compound A and compound B.

Compound B is used in preferably 0.1-5 equivalents, more preferably0.5-2 equivalents, even more preferably 0.9-1.3 equivalents, relative tocompound A.

While the reaction can also be performed without solvent, it ispreferably performed in a solvent. Examples of the solvent includealiphatic hydrocarbon such as pentane, hexane, heptane, cyclohexane andthe like; aromatic hydrocarbon such as toluene, xylene and the like;halogenated hydrocarbon such as dichloromethane, chloroform,dichloroethane and the like; polar solvents such as acetonitrile, DMSO,DMF, DMA, NMP, DMI and the like; ethers such as dioxane, THF, diethylether, cyclopentyl methyl ether, DME, ethylene glycol dimethyl ether andthe like; esters such as methyl acetate, ethyl acetate, isopropylacetate and the like; alcohols such as methanol, ethanol, propanol,2-propanol and the like; water and the like. These may be used alone oras a mixture thereof. Preferred are polar solvents such as DMF, DMA,NMP, DMI and the like. While the amount of the solvent to be used is notparticularly limited, for example, it is used at 0.5-20 v/w relative tocompound A.

The reaction is performed at a temperature of preferably between −50° C.and the boiling point of the solvent to be used, more preferably atemperature between 10° C. and 70° C., even more preferably between 30°C. and 50° C., for generally 5 min-100 hr.

In this step, when a sterically hindered group, for example, tert-butyl,1,1-dimethylpropyl, 1-methyl-1-phenylethyl, trityl and the like ispresent as a substituent —CR⁴R⁵R⁶ on one nitrogen atom of compound A, adesired thiazole ring can be selectively produced (compound C isselectively obtained rather than a compound represented by the followingformula C1):

(wherein R¹, R², R⁴, R⁵ and R⁶ are each as defined above)

Also, when a suitable polar solvent such as DMF, DMA, NMP, DMI and thelike is used, produced compound C can be precipitated as a solid byadding water to the reaction mixture after completion of the reaction,whereby compound C can be obtained by a convenient operation.

Furthermore, compound C is sometimes obtained in the form of a saltcontaining X. Specifically, for example, when X is a chlorine atom,hydrochloride can be obtained, and when X is a bromine atom,hydrobromide and the like can be obtained.

Compound B can be obtained as a commercially available product, oraccording to a known method (for example, Organic Synthesis, IV, 193(1988) and the like). When a commercially available product of compoundB is used, it is used after purification if necessary.

Step 3

Compound D can be obtained by treating compound C with an acid withoutsolvent or in a solvent. The treatment is performed preferably at atemperature between −80° C. and the boiling point of the acid or solventto be used, more preferably at a temperature between 10° C. and 100° C.,for generally 1 min-100 hr, preferably 5 min-24 hr. If necessary, acation scavenger such as anisole and the like is added. The cationscavenger is used in preferably 0.5 equivalent—large excess, morepreferably 1-50 equivalents, relative to compound C.

Examples of the acid include hydrogen halides such as hydrochloric acid,hydrobromic acid, hydroiodic acid and the like; sulfonic acids such asmethanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonicacid, paratoluenesulfonic acid and the like; carboxylic acids such asacetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid,benzoic acid, methylbenzoic acid, trichlorobenzoic acid,trifluorobenzoic acid, pentafluorobenzoic acid and the like; sulfuricacid; nitric acid and the like, preferably hydrochloric acid,trifluoroacetic acid and the like, and it is used in preferably 0.5-200equivalents, more preferably 1-50 equivalents, relative to compound C.

Examples of the solvent include aliphatic hydrocarbons such as pentane,hexane, heptane, cyclohexane and the like; aromatic hydrocarbons such astoluene, xylene and the like; halogenated hydrocarbons such asdichloromethane, chloroform, dichloroethane and the like; polar solventssuch as acetonitrile, DMSO, DMF, DMA, NMP, DMI and the like; ethers suchas dioxane, THF, diethyl ether, cyclopentyl methyl ether, DME, ethyleneglycol dimethyl ether and the like; esters such as methyl acetate, ethylacetate, isopropyl acetate and the like; alcohols such as methanol,ethanol, propanol, 2-propanol and the like; water and the like,preferably toluene, dioxane, water and the like. These are used alone oras a mixture thereof. While the amount of the solvent to be used is notparticularly limited, for example, it is used in 0.5-20 v/w relative tocompound A.

More preferably, for example, compound D can be conveniently obtained ina high yield by treating compound C in 3-12 mol/L hydrochloric acid at atemperature between 50° C. and 100° C.

After the above-mentioned treatment, compound D can be easily obtainedfrom the reaction mixture by, for example, neutralizing the reactionmixture with a suitable base such as lithium hydroxide, sodiumhydroxide, potassium hydroxide, potassium carbonate, sodium carbonateand the like. Compound D can also be easily obtained by performing thetreatment while evaporating a by-produced low boiling point compound,acid and the like by using a Dean-Stark trap and the like. To evaporatethe by-produced low boiling point compound, acid and the like, it isalso effective to perform the reaction under reduced pressure.

Step 4

Compound I can be obtained by reacting compound D and compound E.

(1) When Y in compound E is hydroxy, compound I can be obtained byreacting compound D and compound E in a solvent, in the presence of acondensing agent and, if necessary, in the presence of an additive.

Compound E is preferably used in 0.8-5 equivalents, more preferably 1-2equivalents, relative to compound D.

Examples of the condensing agent include 1,3-dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(EDC), 1,1′-carbonyldiimidazole (CDI), propylphosphonic anhydride (T3P)and the like, and the condensing agent is preferably used in 0.1-10equivalents, more preferably 1-2 equivalents, relative to compound D.

Examples of the additive include 1-hydroxybenzotriazole monohydrate(HOBt H₂O), N-hydroxysuccinimide (HOSu) and the like, and the additiveis preferably used in 0.1-10 equivalents, more preferably 1-2equivalents, relative to compound D.

Examples of the solvent include alcohols such as methanol, ethanol andthe like; halogenated hydrocarbons such as dichloromethane, chloroform,1,2-dichloroethane and the like; aromatic hydrocarbons such as toluene,xylene and the like; esters such as methyl acetate, ethyl acetate,isopropyl acetate and the like; ethers such as dioxane, THF, diethylether, cyclopentyl methyl ether, DME, ethylene glycol dimethyl ether andthe like; polar solvents such as acetonitrile, DMSO, DMF, DMA, NMP, DMIand the like; pyridine; water and the like, preferably polar solventssuch as DMF, DMA, NMP, DMI and the like. These are used alone or as amixture thereof. While the amount of the solvent to be used is notparticularly limited, for example, it is used in 0.5-20 v/w relative tocompound D.

The reaction is performed at a temperature of preferably between 0° C.and the boiling point of the solvent to be used, more preferably 20° C.and 100° C., generally for 5 min-100 hr.

Compound E can be obtained as a commercially available product.

(2) When Y in compound E is halogen, compound I can be obtained byreacting compound D and compound E without solvent or in a solvent, inthe presence of a suitable base as necessary.

Compound E is preferably used in 1-10 equivalents, more preferably 1-2equivalents, relative to compound D.

Examples of the base include potassium carbonate, potassium hydroxide,sodium hydroxide, potassium tert-butoxide, triethylamine,diisopropylethylamine, N-methylmorpholine, pyridine,1,8-diazabicyclo[5.4.0]-7-undecene (DBU), 4-dimethylaminopyridine (DMAP)and the like, and the base is preferably used in 1-10 equivalents, morepreferably 1-2 equivalents, relative to compound D.

Examples of the solvent include alcohols such as methanol, ethanol andthe like; halogenated hydrocarbons such as dichloromethane, chloroform,1,2-dichloroethane and the like; aromatic hydrocarbons such as toluene,xylene and the like; esters such as methyl acetate, ethyl acetate,isopropyl acetate and the like; ethers such as dioxane, THF, diethylether, cyclopentyl methyl ether, DME, ethylene glycol dimethyl ether andthe like; polar solvents such as acetonitrile, DMSO, DMF, DMA, NMP, DMIand the like; pyridine; water and the like, preferably methanol,ethanol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethylacetate, acetonitrile, diethyl ether, THF, DME, dioxane, DMF, DMA, NMP,DMI, pyridine, water and the like. These are used alone or as a mixturethereof. While the amount of the solvent to be used is not particularlylimited, for example, it is used in 0.5-20 v/w relative to compound D.

The reaction is performed at a temperature of preferably between −30° C.and 150° C., more preferably room temperature and 100° C., generally for5 min-100 hr.

Compound E can be obtained as a commercially available product, oraccording to a known method relating to the synthesis of acid chlorideconventionally used in the field of organic synthetic chemistry.

In the above-mentioned (1) and (2), when a polar solvent such as DMF,DMA, NMP, DMI and the like is used, compound I can be precipitated fromthe reaction solution by adding water to the reaction mixture, wherebycompound I can be obtained as a solid by a convenient operation.

The resultant products and intermediates in each of the above-mentionedsteps can be isolated and purified by subjecting to separation andpurification methods conventionally used in the field of organicsynthetic chemistry, for example, filtration, extraction, washing,drying, concentration, recrystallization, various chromatographies andthe like. The resultant products and intermediates in each step can alsobe subjected to the next reaction without particular purification.

Some of the intermediates and resultant products obtained in each stepmay contain stereoisomers such as geometric isomer, optical isomer andthe like, tautomer and the like. The intermediates and resultantproducts in the present invention encompass all possible isomers andmixtures thereof including those mentioned above.

Also, the starting material compounds to be used in each step and theobtained intermediates and resultant products may take the form of saltor solvate.

When a salt of an intermediate or resultant product obtained in eachstep is desired and the intermediate or resultant product obtained ineach step is in the form of a salt, it can be directly purified. When itis obtained in the form of a free form, the intermediate or resultantproduct obtained in each step is dissolved or suspended in a suitablesolvent, an acid or base is added to form a salt and the salt isisolated and purified.

The salt of the starting material compound to be used in each step,intermediate or resultant product obtained in each step encompasses, forexample, acid addition salt, metal salt, ammonium salt, organic amineaddition salt, amino acid addition salt and the like. Examples of theacid addition salt include inorganic acid salts such as hydrochloride,hydrobromide, nitrate, sulfate, phosphate and the like, organic acidsalts such as acetate, oxalate, maleate, fumarate, citrate, benzoate,methanesulfonate and the like, and the like; examples of the metal saltinclude alkali metal salts such as sodium salt, potassium salt and thelike, alkaline earth metal salts such as magnesium salt, calcium saltand the like, aluminum salt, zinc salt and the like; examples of theammonium salt include salts of ammonium, tetramethylammonium and thelike; examples of the organic amine addition salt include addition saltsof morpholine, piperidine and the like; and examples of the amino acidaddition salt include addition salts of lysine, glycine, phenylalanine,aspartic acid, glutamic acid and the like.

When solvates of the starting material compound to be used in each step,the obtained intermediate and the resultant product are desired, theymay be directly obtained by the above-mentioned production method andthe like. They can also obtained by mixing the starting materialcompound to be used in each step, the obtained intermediate or theresultant product with each solvent to form a solvate and subjectingsame to isolation and purification.

According to the above-mentioned production method, compound I can beconveniently obtained by a short step than by known methods (forexample, WO2005/063743). Also, the production method can efficientlyproduce compound I with a certain level of quality and with goodreproducibility, and is preferable as an industrial production method.

As mentioned above, compound I may be present as a salt thereof or asolvate thereof in addition to a free form, and they can be present inthe form of crystals. The crystals of compound I or a salt thereof or asolvate thereof may contain polymorphism and crystal habit. For example,compound I encompasses crystal of compound I, crystal of salt ofcompound I, crystal of solvate of compound I, crystal of solvate of saltof compound I, and crystal polymorphisms thereof, various crystal habitsthereof and the like. More specific examples thereof include anhydridecrystal (A crystal) of compound IA, monohydrate crystal (HA crystal) ofcompound IA, 0.5 ethanolate crystal of compound IA (EA crystal) and thelike, which are shown in the below-mentioned Examples and ReferenceExamples. These crystal forms can be identified, for example, bymeasuring powder X-ray diffraction, the measured values of powder X-raydiffraction described in the present specification were obtained by apermeation method. The measured values (2θ) of powder X-ray diffractionsometimes may vary within the range of ±0.2°.

While a crystal of the above-mentioned compound IA or a monohydratethereof is sometimes directly obtained by the above-mentioned method(step 4), for example, it can be produced by the following method.

In the case of an anhydride crystal (A crystal) of compound IA, compoundIA is dissolved in isobutyl alcohol at a temperature between 50° C. and108° C. (boiling point of isobutyl alcohol), preferably between 70° C.and 100° C., and the mixture is cooled with stirring to a temperaturebetween −5° C. and room temperature, whereby A crystal can be obtainedin a high yield and with good reproducibility.

Isobutyl alcohol is used in, for example, 10-50 v/w, preferably 20-40v/w, more preferably 20-30 v/w, relative to compound IA. Compound IA asa starting material may be a compound obtained in the above-mentionedstep 4 or, for example, a compound obtained in WO 2005/063743, and isnot particularly limited. To maintain quality of a pharmaceuticalproduct, however, a compound having high purity is preferably used. Morepreferably, for example, a monohydrate of compound IA obtained by themethod of the below-mentioned Example 12 and the like may be used. Also,a seed crystal (A crystal) produced separately may be added duringcooling, if necessary.

The above-mentioned seed crystal (A crystal) can be obtained bydissolving compound IA obtained according to the above-mentioned step 4or WO 2005/063743 and the like in isobutyl alcohol at a temperaturebetween 50° C. and 108° C., preferably between 70° C. and 100° C.,cooling the mixture with stirring where necessary to a temperaturebetween −5° C. and room temperature. More preferably, a crystal obtainedby pulverizing the obtained crystal by a jet mill and the like may beused as a seed crystal.

In the case of a monohydrate crystal (HA crystal) of compound IA,moreover, compound IA is dissolved, for example, in a solventsubstantially containing water (for example, DMF-water, ethanol-water,acetone-water and the like) preferably at a temperature between roomtemperature and the boiling point of the solvent to be used, and themixture is cooled with stirring to −5° C.—room temperature, whereby HAcrystal can be obtained in a high yield and with good reproducibility.To obtain a crystal with high purity, crystallization is more preferablyperformed from a mixed solvent of acetone-water.

The solvent substantially containing water is used in, for example,10-50 v/w, preferably 20-40 v/w, more preferably 20-30 v/w, relative tocompound IA, which varies depending on the kind of the solvent to beused. If necessary, a seed crystal (HA crystal) produced separately mayalso be added during cooling.

The above-mentioned seed crystal (HA crystal) can be obtained bydissolving compound IA obtained according to the above-mentioned step 4or WO 2005/063743 and the like in ethanol-water at a temperature between50° C. and 100° C., preferably between 70° C. and 90° C., if necessary,cooling the mixture with stirring to a temperature between −5° C. androom temperature. More preferably, a crystal obtained by pulverizing theobtained crystal by a jet mill and the like may be used as a seedcrystal.

By the above-mentioned method, a crystal of compound IA or a monohydratethereof can be efficiently produced with a certain level of quality andwith good reproducibility.

As mentioned above, compound IA contains crystal forms of anhydride,monohydrate, ethanolate and the like. A crystal that does not transforminto other form even under harsh conditions, for example, hightemperature, high humidity and the like, is particularly superior fromthe aspect of the production of a pharmaceutical product required to besupplied stably. In addition, a crystal superior in oral absorbabilityis desired as a drug substance of an oral pharmaceutical preparation.

For example, in the case of compound IA, compound IA obtained accordingto Example 504 of WO 2005/063743 is 0.5 ethanolate (EA crystal)(Reference Example 3), and crystals of monohydrate, anhydride and thelike can be obtained with good reproducibility by controlling thecrystallization conditions of compound IA. Of these, A crystal and HAcrystal can be specifically obtained by the method described in Examples13-14 with good reproducibility. Of these, A crystal is superior instability (see Experimental Example 1), and can be preserved with acertain quality for a long term.

Such A crystal and HA crystal show superior oral absorbability (seeExperimental Example 2), and are preferable as a drug substance of apharmaceutical product.

A crystal of compound IA or a monohydrate thereof is granulated bypulverization and the like, if necessary, and can be utilized as anactive ingredient of a pharmaceutical preparation, for example, an agentfor the treatment and/or prophylaxis of diseases such as Parkinson'sdisease, sleep disorder, analgesic resistance to opioid, migraine,movement disorder, depression, anxiety disorder and the like.

While a crystal of compound IA or a monohydrate thereof can beadministered as it is, it is generally desirably provided as variouspharmaceutical preparations. Such pharmaceutical preparations are usedfor animal or human.

The pharmaceutical preparations can contain, as an active ingredient, acrystal of compound IA or a monohydrate thereof singly or as a mixturewith any other active ingredient for the treatment. Such pharmaceuticalpreparations are produced by mixing the active ingredient with one ormore kinds of pharmaceutically acceptable carriers (for example,diluent, solvent, excipient and the like), and according to any methodwell known in the technical field of the drug formulation study.

As the administration route, one most effective for the treatment isdesirably used, which may be oral or, for example, parenteral such asintravenously and the like.

Examples of the administration form include tablet, externalpreparation, injection and the like.

For example, tablet and the like suitable for oral administration can beproduced using excipients such as lactose and the like, disintegrantssuch as starch and the like, lubricants such as magnesium stearate andthe like, binders such as hydroxypropylcellulose and the like, and thelike.

Examples of the external preparation and the like suitable forparenteral administration include ointment, cream, liniment, lotion,poultice, plaster, tape and the like. For example, ointment, cream andthe like can be produced by dissolving or mixed-dispersing the activeingredient in a base such as white petrolatum and the like. Also, forexample, injection and the like can be produced using a diluent, asolvent and the like such as salt solution, glucose solution or amixture of salt water and glucose solution, and the like.

The dose and administration frequency of a crystal of compound IA or amonohydrate thereof vary depending on the administration form, age, bodyweight of patients, properties or severity of the symptoms to betreated, and the like. For oral administration, 0.01-1000 mg, preferably0.05-100 mg, is generally administered per adult in one to severalportions per day. For parenteral administration such as intravenousadministration and the like, 0.001-1000 mg, preferably 0.01-100 mg, isgenerally administered per adult once to several times per day. However,these doses and administration frequencies vary depending on theaforementioned various conditions.

The present invention is more specifically explained in the following byreferring to Examples and Reference Examples, which are not to beconstrued as limitative.

The proton nuclear magnetic resonance spectrum (¹H NMR) used in theExamples and Reference Examples were measured at 270 MHz or 300 MHz, andexchanging proton may not be observed clearly depending on the compoundand measurement conditions. For indication of signal multiplicity, thosegenerally used are employed, wherein br means an apparently broadsignal.

Powder X-ray diffraction (permeation method) was measured by pulverizinga sample in an agate mortar, placing an appropriate amount thereof on asample plate, and measuring diffraction peaks by changing thediffraction angle 2θ from 5° to 40°. The irradiate X ray used was copperKα ray (CuKα ray), and tube voltage was set to 5 kV, tube electriccurrent was set to 40 mA, step angle was set to 0.017°, and countingtime was set to 0.56°/sec. The thermal analysis was performed by placingabout 2 mg of a sample on an aluminum cell, and measuring differentialscanning calorie (DSC) at a temperature rise rate of 10° C./min.

[Example 1] Production of4-(furan-2-yl)-2-tert-butylaminothiazol-5-yl=pyridin-2-yl=ketone(Compound C-1)

Compound A-1 (228 mg, 1.0 mmol) obtained in Reference Example 1 and2-(bromoacetyl)pyridine hydrobromide (281 mg, 1.0 mmol) were dissolvedin DMF (2.8 mL) and the mixture was stirred at 40° C. for 9 hr. To themixture was added water (4.0 mL), and the mixture was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The residue was purified by silica gel column chromatography(n-hexane:ethyl acetate=9:1) to give compound C-1 (271 mg, 82%).

¹H-NMR (CDCl₃) δ 1.50 (s, 9H), 6.03 (brs, 1H), 6.51 (dd, J=3.5 Hz, 1.8Hz, 1H), 7.42 (ddd, J=7.9 Hz, 4.9 Hz, 1.0 Hz, 1H), 7.44 (dd, J=1.8 Hz,0.7 Hz, 1H), 7.79 (dd, J=3.5 Hz, 0.7 Hz, 1H), 7.86 (td, J=7.9 Hz, 1.8Hz, 1H), 8.13 (ddd, J=7.9 Hz, 1.0 Hz, 0.9 Hz, 1H), 8.63 (ddd, J=4.9 Hz,1.8 Hz, 0.9 Hz, 1H). LC/MS ESI(+) m/z 328 [M+H]⁺.

[Example 2] Production of4-(furan-2-yl)-2-tert-butylaminothiazol-5-yl=pyridin-3-yl=ketone(Compound C-2)

Compound A-1 (218 mg, 0.96 mmol) obtained in Reference Example 1 and3-(bromoacetyl)pyridine hydrobromide (278 mg, 1.0 mmol) were dissolvedin DMF (2.0 mL) and the mixture was stirred at 40° C. for 10 hr. To themixture was added water (4.0 mL), and the mixture was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The residue was purified by silica gel column chromatography(n-hexane:ethyl acetate=7:3) to give compound C-2 (207 mg, 66%).

¹H-NMR (CDCl₃) δ 1.48 (s, 9H), 6.19 (brs, 1H), 6.31 (dd, J=3.5 Hz, 1.8Hz, 1H), 6.87 (dd, J=3.5 Hz, 0.6 Hz, 1H), 7.07 (dd, J=1.8 Hz, 0.6 Hz,1H), 7.26 (dd, J=8.1 Hz, 5.0 Hz, 1H), 7.92 (ddd, J=8.1 Hz, 2.2 Hz, 1.7Hz, 1H), 8.62 (dd, J=5.0 Hz, 1.7 Hz, 1H), 8.82 (dd, J=2.2 Hz, 0.7 Hz,1H). LC/MS ESI(+) m/z 328 [M+H]⁺.

[Example 3] Production of4-(furan-2-yl)-2-tert-butylaminothiazol-5-yl=tetrahydropyran-4-yl=ketone(Compound C-3)

Compound A-1 (30 mg, 0.13 mmol) obtained in Reference Example 1 and4-bromoacetyltetrahydropyran (25 mg, 0.12 mmol) were dissolved in DMF(0.5 mL) and the mixture was stirred at 40° C. for 8.5 hr. To themixture was added water (0.5 mL), and the precipitated solid wascollected by filtration. The obtained solid was washed with water (0.5mL), and dried under reduced pressure to give compound C-3 (37 mg, 92%).

¹H-NMR (CDCl₃) δ 1.46 (s, 9H), 1.60-1.95 (m, 4H), 3.06 (tt, J=11.1 Hz,3.9 Hz, 1H), 3.40 (dt, J=11.6 Hz, 2.2 Hz, 2H), 4.02 (ddd, J=11.6 Hz, 4.2Hz, 2.2 Hz, 2H), 5.81 (brs, 1H), 6.55 (dd, J=3.5 Hz, 1.8 Hz, 1H), 7.48(dd, J=3.5 Hz, 0.7 Hz, 1H), 7.54 (dd, J=1.8 Hz, 0.7 Hz, 1H). LC/MSESI(+) m/z 335 [M+H]⁺.

[Example 4] Production of4-(furan-2-yl)-2-(1-methyl-1-phenylethyl)aminothiazol-5-yl=tetrahydropyran-4-yl=ketone(Compound C-4)

Compound A-2 (580 mg, 2.0 mmol) obtained in Reference Example 2 and4-bromoacetyltetrahydropyran (416 mg, 2.0 mmol) were dissolved in DMF(2.0 mL) and the mixture was stirred at 40° C. for 8 hr. Underice-cooling, the mixture was neutralized with saturated aqueous sodiumhydrogen carbonate solution, and the mixture was extracted with ethylacetate. The organic layer was washed with saturated brine, dried overanhydrous magnesium sulfate and concentrated under reduced pressure. Theresidue was purified by silica gel column chromatography (n-hexane:ethylacetate=4:1-1:1) to give compound C-4 (690 mg, 87%).

¹H-NMR (CDCl₃) δ 1.53-1.83 (m, 4H), 1.76 (s, 6H), 2.79 (tt, J=12.9 Hz,3.7 Hz, 1H), 3.29 (dt, J=11.6 Hz, 2.3 Hz, 2H), 3.94 (ddd, J=11.6 Hz, 3.6Hz, 2.3 Hz, 2H), 6.54 (dd, J=3.5 Hz, 1.7 Hz, 1H), 6.76 (brs, 1H),7.28-7.42 (m, 3H), 7.44-7.51 (m, 3H), 7.54 (dd, J=1.7 Hz, 0.8 Hz, 1H).

[Example 5] Production of2-amino-4-(furan-2-yl)thiazol-5-yl=pyridin-2-yl=ketone (Compound D-1)

Compound C-1 (263 mg, 0.80 mmol) obtained in Example 1 was dissolved inconcentrated hydrochloric acid (2.6 mL), and the mixture was stirred at80° C. for 3.5 hr. Under ice-cooling, the mixture was neutralized withsaturated aqueous sodium hydrogen carbonate solution, and theprecipitated solid was collected by filtration. The obtained solid waswashed with water (6.0 mL), and dried under reduced pressure to givecompound D-1 (140 mg, 64%).

¹H-NMR (DMSO-d₆) δ 6.56 (dd, J=3.5 Hz, 1.7 Hz, 1H), 7.44 (dd, J=3.5 Hz,0.7 Hz, 1H), 7.53-7.61 (m, 2H), 7.94-8.08 (m, 2H), 8.05 (brs, 2H), 8.57(ddd, J=5.0 Hz, 1.7 Hz, 0.9 Hz, 1H). LC/MS ESI(+) m/z 272 [M+H]⁺.

[Example 6] Production of2-amino-4-(furan-2-yl)thiazol-5-yl=pyridin-3-yl=ketone (Compound D-2)

Compound C-2 (207 mg, 0.63 mmol) obtained in Example 2 was dissolved inconcentrated hydrochloric acid (2.0 mL), and the mixture was stirred at80° C. for 3.5 hr. Under ice-cooling, the mixture was neutralized withsaturated aqueous sodium hydrogen carbonate solution, and theprecipitated solid was collected by filtration. The obtained solid waswashed with water (3.0 mL), and dried under reduced pressure to givecompound D-2 (127 mg, 74%).

¹H-NMR (DMSO-d₆) δ 6.40 (dd, J=3.5 Hz, 1.8 Hz, 1H), 6.80 (dd, J=3.5 Hz,0.4 Hz, 1H), 7.28 (dd, J=1.8 Hz, 0.4 Hz, 1H), 7.35 (ddd, J=8.0 Hz, 4.9Hz, 0.6 Hz, 1H), 7.85 (ddd, J=8.0 Hz, 2.2 Hz, 1.8 Hz, 1H), 8.15 (brs,2H), 8.60 (dd, J=4.9 Hz, 1.8 Hz, 1H), 8.63 (dd, J=2.2 Hz, 0.6 Hz, 1H).LC/MS ESI(+) m/z 272 [M+H]⁺.

[Example 7] Production of2-amino-4-(furan-2-yl)thiazol-5-yl=tetrahydropyran-4-yl=ketone (CompoundD-3)—(1)

Compound C-3 (30 mg, 0.09 mmol) obtained in Example 3 was dissolved inconcentrated hydrochloric acid (1.0 mL), and the mixture was stirred at80° C. for 1.5 hr. Under ice-cooling, the mixture was neutralized withsaturated aqueous sodium hydrogen carbonate solution, and theprecipitated solid was collected by filtration. The obtained solid waswashed with water (0.5 mL), and dried under reduced pressure to givecompound D-3 (22 mg, 87%).

¹H-NMR (CDCl₃) δ 1.68-1.95 (m, 4H), 2.99 (tt, J=11.0 Hz, 3.9 Hz, 1H),3.40 (dt, J=11.6 Hz, 2.4 Hz, 2H), 4.02 (ddd, J=11.6 Hz, 4.0 Hz, 2.4 Hz,2H), 5.58 (brs, 2H), 6.56 (dd, J=3.5 Hz, 1.8 Hz, 1H), 7.55 (d, J=3.5 Hz,1H), 7.56 (d, J=1.8 Hz, 1H). LC/MS ESI(+) m/z 279 [M+H]⁺.

[Example 8] Production of Compound D-3—(2)

A mixture of compound C-3 (80 g, 0.24 mol) obtained in Example 3,concentrated hydrochloric acid (200 mL) and water (200 mL) was stirredat 95-108° C. for 4 hr while evaporating low boiling substances. To themixture was added dropwise at 95° C. warm water (80 mL) at 90° C., andthe mixture was stirred at the same temperature for 30 min and then at85° C. for 30 min, and cooled to 50° C. Methanol (240 mL) was addeddropwise. The mixture was adjusted to pH 9.5 with aqueous sodiumhydroxide solution (8 mol/L), cooled to 5° C., and the precipitatedsolid was collected by filtration. The obtained solid was washed withcold 10% aqueous methanol solution, and dried under reduced pressure togive compound D-3 (61 g, 92%). [Example 9] Production of compoundD-3—(3)

Compound C-4 (50 mg, 0.13 mmol) obtained in Example 4 was dissolved intrifluoroacetic acid (0.5 mL), and the mixture was stirred at 40° C. for3 hr. Under ice-cooling, the mixture was neutralized with saturatedaqueous sodium hydrogen carbonate solution, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated brine, dried over anhydrous magnesium sulfate and concentratedunder reduced pressure. The residue was purified by thin layer silicagel column chromatography (n-hexane:ethyl acetate=1:1) to give compoundD-3 (21 mg, 59%).

[Example 10] Production ofN-[4-(furan-2-yl)-5-(tetrahydrofuran-4-carbonyl)thiazol-2-yl]-6-methylpyridine-3-carboxamide(Compound IA) monohydrate

A mixture of compound D-3 (500 g, 1.80 mol) obtained in Example 7,activated carbon (C2, 25 g) and DMF (1.3 L) was stirred at 60° C. for 1hr. The activated carbon was filtered off at the same temperature, tothe filtrate were added 6-methylnicotinic acid (419 g, 3.06 mol), CDI(495 g, 3.06 mol) and DMF (875 mL) at room temperature, and the mixturewas stirred at 90° C. for 3 hr. The mixture was cooled to 60° C.,activated carbon (C2, 50 g) and DMF (250 mL) were added, and the mixturewas stirred at the same temperature for 1 hr. The activated carbon wasfiltered off at the same temperature, and washed with DMF (500 mL) atthe same temperature. The filtrate was cooled to 40° C., water (1.5 L)was added dropwise over 30 min with stirring at the same temperature,and the mixture was stirred at the same temperature for 30 min. Water(1.5 L) was further added dropwise. The mixture was cooled to 5° C.,stirred for 6 hr, and the precipitated solid was collected byfiltration. The obtained solid was washed with cold 50% aqueous methanolsolution (1.0 L), and dried under reduced pressure to give compound IAmonohydrate (619 g, yield 84%).

[Example 11] Production of Compound IA Monohydrate Crystal (HA Crystal)

Compound IA monohydrate (80 g, 0.19 mol) obtained in Example 10 wasdissolved in a mixed solvent of water (0.56 L) and acetone (2.24 L) at55° C., activated carbon (C2, 8 g) was added and the mixture was stirredfor 30 min. The activated carbon was filtered off at the sametemperature, and washed with warm 80% aqueous acetone solution (0.16 L).HA crystal (0.40 g) obtained in Example 13 was added as a seed crystalwhile stirring the filtrate at 40° C., and the mixture was cooled to 0°C. over 3 hr, and stirred at the same temperature for 15 hr. Theprecipitated solid was collected by filtration, the obtained solid waswashed with cold 50% aqueous acetone solution (0.10 L), and dried underreduced pressure at 45° C. for 48 hr to give compound IA HA crystal (72g, yield 90%).

powder X-ray diffraction measurement results: peaks at diffractionangles (2θ)=8.1, 12.0, 14.7, 16.3, 21.1, 21.8, 23.0, 24.4, 24.7, 28.3°(see FIG. 1).

thermal analysis (DSC) measurement results: endothermic peaks at about133° C. and about 209° C.

[Example 12] Production of Compound IA Anhydride Crystal (A Crystal)

Compound IA monohydrate (300 g, 0.72 mol) obtained in Example 10 wasdissolved in isobutyl alcohol (8.1 L) at 80° C., activated carbon (C2,30 g) was added and the mixture was stirred for 30 min. The activatedcarbon was filtered off at the same temperature, and washed with warmisobutyl alcohol (0.6 L). The A crystal (1.5 g) obtained in Example 14was added as a seed crystal to the filtrate while stirring the filtrateat 70° C. The mixture was further stirred at the same temperature for 1hr, cooled to 5° C. over 6 hr, and further stirred at the sametemperature for 18 hr. The precipitated solid was collected byfiltration, the obtained solid was washed with cold isobutyl alcohol(0.60 L), and dried under reduced pressure at 50° C. to give A crystal(262 g, yield 93%).

powder X-ray diffraction measurement results: peaks at diffractionangles (2θ)=8.3, 12.6, 16.5, 19.1, 19.5, 20.8, 21.2, 22.4, 23.8, 27.0°(see FIG. 2).

thermal analysis (DSC) measurement results: endothermic peak at about210° C.

[Example 13] Production of Seed Crystal of HA Crystal

Compound IA monohydrate (550 g, 1.38 mol) obtained in Example 10 wasdissolved in a mixed solvent of water (1.1 L) and ethanol (9.9 L) at 80°C. The solution was added dropwise to water (1.1 L) over 20 min, and themixture was stirred at 20° C. for 1.5 hr, and further at 0° C. for 2.5hr. The precipitated solid was collected by filtration, the obtainedsolid was washed with a mixed solvent (400 mL) of cold water (320 mL)and cold ethanol (80 mL), and dried under reduced pressure at 55° C. togive HA crystal (525 g, yield 95%).

The HA crystal (515 g) was pulverized by a jet mill and the pulverizedcrystal was used as a seed crystal.

powder X-ray diffraction measurement results: peaks at diffractionangles (2θ)=8.1, 12.0, 14.7, 16.3, 21.1, 21.8, 23.0, 24.4, 24.7, 28.3°.

[Example 14] Production of Seed Crystal of a Crystal

Compound IA monohydrate (40 g, 96 mmol) obtained in Example 10 wasdissolved in isobutyl alcohol (1.2 L) at 80° C., and the solution wascooled to 5° C. over 8 hr. The solution was further stirred at the sametemperature for 16 hr, the precipitated solid was collected byfiltration, the obtained solid was washed with cold isobutyl alcohol (80mL), and dried under reduced pressure at 50° C. to give A crystal (37 g,yield 95%). The A crystal (34 g) was pulverized by a jet mill. Thepulverized crystal was used as a seed crystal.

powder X-ray diffraction measurement results: peaks at diffractionangles (2θ)=8.3, 12.6, 16.5, 19.1, 19.5, 20.8, 21.2, 22.4, 23.8, 27.0°.

(Reference Example 1) Production of 1-tert-butyl-3-(furan-2-yl)carbonylthiourea (Compound A-1)

Sodium thiocyanate (0.91 g, 11 mmol) was suspended in THF (5.0 mL),2-furoyl chloride (1.0 mL, 10 mmol) was added at 40° C., and the mixturewas stirred for 10 min. After ice-cooling, tert-butylamine (1.1 mL, 11mmol) was added to the mixture, and the mixture was stirred at 40° C.for 30 min. Water (10.0 mL) was added to the mixture, and the mixturewas stirred at room temperature for 30 min. The precipitated solid wascollected by filtration, washed with water (5.0 mL), and dried underreduced pressure to give compound A-1 (1.86 g, 81%).

¹H-NMR (CDCl₃) δ 1.59 (s, 9H), 6.59 (dd, J=3.6 Hz, 1.7 Hz, 1H), 7.29(dd, J=3.6 Hz, 0.8 Hz, 1H), 7.57 (dd, J=1.7 Hz, 0.8 Hz, 1H), 8.86 (brs,1H), 10.62 (brs, 1H). LC/MS (ESI(+)) m/z 227 [M+H]⁺.

(Reference Example 2) Production of1-(1-methyl-1-phenylethyl)-3-(furan-2-yl)carbonylthiourea (Compound A-2)

Sodium thiocyanate (922 mg, 11 mmol) was suspended in THF (5.0 mL),2-furoyl chloride (1.0 mL, 10 mmol) was added at 40° C., and the mixturewas stirred for 10 min. After ice-cooling, 1-methyl-1-phenylethylamine(1.5 mL, 11 mmol) was added to the mixture, and the mixture was stirredat room temperature for 1.5 hr. Water (10.0 mL) was added to themixture, and the mixture was extracted with ethyl acetate. The organiclayer was washed with saturated brine, dried over anhydrous magnesiumsulfate, and concentrated under reduced pressure. Ethanol (3.0 mL) wasadded to the obtained residue and the mixture was stirred, and theprecipitated solid was collected by filtration, and dried under reducedpressure to give compound A-2 (1.85 g, 63%).

¹H-NMR (CDCl₃) δ 1.90 (s, 6H), 6.60 (dd, J=3.6 Hz, 1.7 Hz, 1H),7.20-7.42 (m, 5H), 7.33 (dd, J=3.6 Hz, 0.8 Hz, 1H), 7.57 (dd, J=1.7 Hz,0.8 Hz, 1H), 8.91 (brs, 1H), 11.05 (brs, 1H).

(Reference Example 3) Production of Compound IA by the Method Describedin WO2005/063743 (Production of Compound IA 0.5 Ethanolate (EA Crystal))

In the same manner as in Example 504 of WO 2005/063743, compound IA wasobtained as a pale-brown solid. The obtained solid was confirmed to becompound IA 0.5 ethanolate crystal (EA crystal) from various spectrumdata (¹H NMR spectrum, powder X-ray diffraction, thermal analysis,elemental analysis and the like).

powder X-ray diffraction measurement results: peaks at diffractionangles (2θ)=7.4, 9.0, 10.0, 12.7, 16.3, 17.7, 19.3, 19.8, 23.9, 27.2°(see FIG. 3).

thermal analysis (DSC) measurement results: endothermic peaks at about154° C., about 198° C. and about 208° C.

Experimental Example 1: Stability Test

The A crystal obtained in Example 12 was preserved under the conditionsof 40° C./75% RH (relative humidity) and 40° C./90% RH (relativehumidity) for 6 months each, and powder X-ray diffraction was measured.When compared with the diffraction pattern at the time of the start ofthe preservation, the diffraction pattern did not show any change underthe both conditions. It was confirmed that A crystal is stable evenafter preservation for a long term under humidified conditions of 40°C./75% RH (relative humidity) and 40° C./90% RH (relative humidity).

The HA crystal obtained in Example 11 was preserved for 2 weeks at 60°C., and then powder X-ray diffraction was measured. When compared withthe diffraction pattern at the time of the start of the preservation,the diffraction pattern after preservation was confirmed to show adiffraction peak characteristic of A crystal. That is, a part of HAcrystal is considered to undergo crystal transition to A crystal at 60°C.

Experimental Example 2: Absorbability Test

HA crystal and A crystal obtained in Examples 11 and 12 were orallyadministered to male rats respectively, and plasma kinetics of compoundIA were evaluated. The results are shown in Table 1 and Table 2.

TABLE 1 Plasma kinetics of HA crystal t_(max) C_(max) t_(1/2) AUC_(0→∞)BA dose (h) (ng/mL) (h) (ng · h/mL) (%)  1 mg/kg 1.33 ± 1500 ± 2.08 ±5930 59.5 0.58 100 0.13 10 mg/kg 2.00 ± 10900 ± 3.43 ± 56600 56.8 0.00800 1.14

TABLE 2 Plasma kinetics of A crystal t_(max) C_(max) t_(1/2) AUC_(0→∞)BA dose (h) (ng/mL) (h) (ng · h/mL) (%)  1 mg/kg 1.00 ± 1410 ± 2.26 ±5350 53.7 0.00 270 0.26 10 mg/kg 1.67 ± 11400 ± 1.77 ± 51000 51.2 0.581400 0.09

As a result, both HA crystal and A crystal showed good bioavailability,and they were confirmed to have superior properties as pharmaceuticalproducts.

The plasma concentration increased more rapidly in A crystal than in HAcrystal.

INDUSTRIAL APPLICABILITY

According to the present invention, a production method of a compoundrepresented by the formula (I), which has an adenosine A_(2A) receptorantagonistic action and is useful as a therapeutic agent for, forexample, Parkinson's disease, sleep disorder, analgesic resistance toopioid, migraine, movement disorder, depression, anxiety disorder andthe like, a crystal of a compound represented by the formula (IA) or amonohydrate thereof and a production method thereof and the like can beprovided. The production methods of the present invention are useful asindustrial production methods of a drug substance of a pharmaceuticalproduct. Also, a crystal form of a compound represented by the formula(IA) or a monohydrate thereof of the present invention is useful as adrug substance of a pharmaceutical product.

This application is a divisional of application Ser. No. 15/541,857filed Jul. 6, 2017, which is a national phase of PCT Application No.PCT/JP2016/051197 filed Jan. 8, 2016, which in turn is based on patentapplication No. 2015-2964 filed Jan. 9, 2015 in Japan, the contents ofwhich are incorporated in full herein.

The invention claimed is:
 1. An anhydrous crystal of a compoundrepresented by formula (IA)

said anhydrous crystal having at least one peak at 8.3°, 20.8°, 21.2° or22.4° for the angles of diffraction (2θ±0.2°) as determined by powderX-ray diffraction.
 2. The crystal according to claim 1, which has peaksat 8.3° and 19.1° for the angles of diffraction (2θ±0.2°) as determinedby powder X-ray diffraction.
 3. The crystal according to claim 1, whichhas peaks at 21.2°, 23.8° and 27.0° for the angles of diffraction(20±0.2°) as determined by powder X-ray diffraction.
 4. A productionmethod of the crystal described in claim 1, comprising a step ofcrystallizing a compound represented by the formula (IA) from isobutylalcohol.
 5. The crystal according to claim 2, which has peaks at 21.2°,23.8° and 27.0° for the angles of diffraction (20±0.2°) as determined bypowder X-ray diffraction.
 6. A production method of the crystaldescribed in claim 2, comprising a step of crystallizing a compoundrepresented by the formula (IA) from isobutyl alcohol.
 7. A productionmethod of the crystal described in claim 3, comprising a step ofcrystallizing a compound represented by the formula (IA) from isobutylalcohol.
 8. A production method of the crystal described in claim 5,comprising a step of crystallizing a compound represented by the formula(IA) from isobutyl alcohol.